Decisions of the Unified Patent Court recorded under "Milan (IT) Central Division- Section" in UPC Litigation Watch, the case law database maintained by Dhenne Avocats.
UPC decisions and orders since 1 June 2023. “Decision with commentary” means the entry contains an analysis by Dhenne Avocats. “Summary available” identifies a summary; “Reference” identifies a record without a detailed case note. Open the entry for the source and, where available, the facts, reasoning and practical implications. The official decision is authoritative.
Combinable filters, search within the records or the full text of the decisions, copy reference, selection and export. The keyword and reference search above remains available.
49 decisions recorded
By order of 22 October 2026, the Milan section of the Central Division rules on Novo Nordisk A/S’s preliminary objection to three ancillary requests in the revocation action brought by Sandoz AG against unitary patent EP 3 689 365, on once-weekly semaglutide.
Read the analysisIn a decision of 9 October 2026 (UPC_CFI_1587/2025), the Milan section of the Central Division dismissed Biogaran’s revocation action against EP 4 223 296, held by H.
Read the analysisIn a decision of 19 August 2026 (UPC_CFI_860/2025), the Milan Central Division rules on LS9 GmbH's revocation action against Bellissa HAAS GmbH's EP 2 223 589 (a bed edging with a lockable sheet-metal strip), limited to Germany, Austria and Luxembourg.
Read the analysisIn a decision of 10 July 2026 (UPC_CFI_1968/2026), the judge-rapporteur of the Milan Central Division orders the Academy of Military Medical Sciences (AMMS), proprietor of EP 3 854 403, to pay Gilead Sciences EUR 800,000 in recoverable costs within four weeks of…
Read the analysisIn an order of 12 June 2026 (UPC_CFI_1230/2026), the judge-rapporteur of the Milan Central Division orders EOFLOW to pay Insulet EUR 14,000 for the costs incurred in the application for leave to appeal (UPC_CFI_1167/2025) and in the appeal concerning a penalty payment…
Read the analysisBy a Rule 105 RoP order of 27 May 2026, made after the interim conference of 13 May 2026 (UPC_CFI_860/2025), the judge-rapporteur of the Milan Central Division, in LS 9 GmbH's revocation action against Bellissa HAAS GmbH's EP 2223589, prepared the oral…
Read the analysisBy order of 19 May 2026 (UPC_CFI_927/2025), the panel of the Milan Central Division ruled on the confidentiality application by La Siddhi Consultancy, claimant in the revocation action against unitary patent EP 3 592 333 brought against Athena Pharmaceutiques and Substipharm, concerning…
Read the analysisIn a decision of 4 May 2026 (UPC_CFI_552/2025), the Milan Central Division grants Gilead Sciences' revocation action and revokes in its entirety the Academy of Military Medical Sciences' unitary patent EP 3 854 403, which claimed the use of remdesivir to treat…
Read the analysisIn a decision of 10 April 2026 (UPC_CFI_480/2025), the Milan Central Division revokes in its entirety, for all UPC Contracting Member States, Flexicare's unitary patent EP 4 185 356 on a nasal cannula, in a revocation action brought by Fisher & Paykel…
Read the analysisBy an order of 13 March 2026 (UPC_CFI_927/2025), the Milan Central Division, ordered La Siddhi Consultancy, the UK claimant in the revocation action against unitary patent EP 3 592 333, to provide within six weeks security of EUR 75,000 for the costs…
Read the analysisBy an order of 13 March 2026 (UPC_CFI_722/2025), the Milan Central Division found that Neurocrine Biosciences' revocation action against Spruce Biosciences' unitary patent EP 3 784 233 had become devoid of purpose following the final revocation of the patent by the EPO,…
Read the analysisBy an order of 15 January 2026 (UPC_CFI_480/2025), the Milan Central Division refused to admit auxiliary requests 2A to 13A, filed "as a mere precaution" by Flexicare, proprietor of EP 4 185 356, in its rejoinder in Fisher & Paykel Healthcare's revocation…
Read the analysisThe Milan Central Division ordered EOFLOW to pay a penalty of EUR 150,000 for violating the preliminary injunction granted by the Court of Appeal on 30 April 2025, on the basis of evidence that EOFLOW had exported 11,520 insulin pump devices to…
Read the analysisBy decision of 27 November 2025, the Milan Central Division, hearing Pari Pharma’s revocation action against Koninklijke Philips’ EP 3 397 329 B1 (air-flow in a nebulizer head), holds claim 1 as granted to lack novelty but maintains the patent as amended…
Read the analysisBy decision of 23 October 2025 (UPC_CFI_497/2024, revocation action, and UPC_CFI_571/2024, revocation counterclaim), the Milan Central Division ruled on the validity of Labrador Diagnostics' EP 3 756 767, concerning modular point-of-care devices, challenged by bioMérieux UK and several bioMérieux group companies.
Read the analysisIn an order of 16 October 2025, the judge-rapporteur of the Milan Central Division partly granted Herbert Smith Freehills Kramer's request for access to the file of the proceedings Insulet v EOFLOW (UPC_CFI_380/2024).
Read the analysisIn a decision of 15 October 2025, the judge-rapporteur of the Milan Central Division assessed the recoverable costs payable by EOFLOW to Insulet following the decision on the merits of 22 July 2025 (proceedings UPC_CFI_773/2025 and UPC_CFI_774/2025, patent EP 4 201 327).
Read the analysisBy an order of 4 September 2025 (UPC_CFI_552/2025, ORD_36084/2025), the judge-rapporteur of the Milan Central Division declared inadmissible the request for a decision by default made by Gilead Sciences in its revocation action against the Academy of Military Medical Sciences' patent EP…
Read the analysisBy order of 6 August 2025 (UPC_CFI_628/2025), the standing judge of the Milan Central Division (Judge Postiglione, sitting alone under Rule 97.4 RoP and Article 19 of the Statute) dismissed the action brought by Bodycap, CNRS and Université de Rennes against the…
Read the analysisBy a decision of 31 July 2025 (UPC_CFI_382/2025), the judge-rapporteur of the Milan Central Division ruled on the costs claimed by Novartis from ZENTIVA K.S. and ZENTIVA PORTUGAL following the dismissal, on 21 March 2025, of their application to intervene in an…
Read the analysisIn a decision of 22 July 2025 (UPC_CFI_597/2024), given both on EOFLOW’s revocation action and on Insulet’s counterclaim for infringement, the Milan Central Division dismissed by default the revocation action against unitary patent EP 4 201 327, EOFLOW having refused to provide…
Read the analysisBy decision by default of 8 July 2025, the Milan Central Division (Postiglione, Klein, Ledeboer) held that the “Bellota” tool marketed by the Greek company Spiridonakis Bros infringes claims 1, 2, 3, 5, 6, 9 and 10 of EP 1 998 604,…
Read the analysisOn Insulet's application in its claim against EOFLOW for the costs of the provisional measures proceedings on EP 4 201 327, the judge rapporteur of the Milan Central Division partly protected the fee evidence filed.
Read the analysisBy decision of 22 July 2025, the Milan Central Division dismissed by default EOFLOW's revocation action against EP 4 201 327 (unitary effect), EOFLOW having failed to provide the EUR 500,000 security ordered on 11 April 2025, and then, after examining the…
Read the analysisBy order of 15 May 2025 (ORD_22310/2025), the judge rapporteur of the Milan Central Division ordered, in the action for infringement of EP 1 998 604 brought by Maschio Gaspardo against Spiridonakis Bros, which did not appear (UPC_CFI_513/2024), an on-site inspection of…
Read the analysisBy order of 22 April 2025 (UPC_CFI_476/2024, ORD_18700/2025), the Milan Central Division allowed, with the consent of GlaxoSmithKline Biologicals, the withdrawal of the revocation action (ACT_45928/2024) and of the counterclaim for revocation (CC_60908/2024, referred by the Düsseldorf Local Division) brought by Pfizer…
Read the analysisBy order of 22 April 2025 (UPC_CFI_687/2024, ORD_18810/2025), the Milan Central Division allowed, with the consent of GlaxoSmithKline Biologicals, the withdrawal of the revocation action against EP 4 183 412 brought by Pfizer companies and of their counterclaim for revocation, referred by…
Read the analysisBy order of 11 April 2025 (UPC_CFI_597/2024), the Milan Central Division rules on three issues in EOFLOW’s revocation action against Insulet’s EP 4201327, in which Insulet has counterclaimed for infringement.
Read the analysisBy order of 10 April 2025 (UPC_CFI_698/2024, ORD_12069/2025), Judge-rapporteur Postiglione (Milan Central Division) granted ALIUD PHARMA, a third party to the action for a declaration of non-infringement of EP 2 501 384 brought by Accord Healthcare against Novartis, access to the statement…
Read the analysisBy order of 27 March 2025 (UPC_CFI_698/2024, ORD_10348/2025), the Milan Central Division (Judges Postiglione, presiding and rapporteur, Knijff and Werner, technically qualified) dismissed the application by ZENTIVA K.S.
Read the analysisBy order of 27 February 2025 (UPC_CFI_604/2024, ACT_57037/2024, ORD_7507/2025, published under Applications App_5729/2025 and App_5962/2025), the Milan Central Division (Judges Postiglione, presiding, Knijff, rapporteur, and Weber) allowed SharkNinja Italy to withdraw its revocation action against Dyson Technology's EP 2 043 492, following…
Read the analysisBy an order of 15 February 2025 (ORD_65815/2024, UPC_CFI_380/2024), Andrea Postiglione, judge rapporteur in the Milan Central Division, dismissed without examining the substance EOFLOW Co., Ltd.'s application for its costs in the provisional measures proceedings brought by Insulet Corporation on EP 4…
Read the analysisBy an order of 3 February 2025 (UPC_CFI_698/2024, ORD_68703/2024), the Milan Central Division (Judges Postiglione, presiding and rapporteur, Knijff and Werner) dismissed the request by STADAPHARM, a non-party, for access to the file in the action for a declaration of non-infringement brought…
Read the analysisBy an order of 23 December 2024 (UPC_CFI_380/2024, ORD_59988/2024), the judge-rapporteur of the Milan Central Division (Judge Postiglione) ordered A. Menarini Diagnostics to pay Insulet EUR 1,764 for the costs of opposing its application to intervene, refused on 1 October 2024, in…
Read the analysisBy order of 2 December 2024 (UPC_CFI_476/2024, ACT_45928/2024, ORD_58802/2024), the Milan Central Division dismissed GlaxoSmithKline Biologicals' preliminary objection to Pfizer's revocation action against EP 4 183 412.
Read the analysisBy order of 22 November 2024 (UPC_CFI_380/2024), made after the hearing of 16 October 2024, the Milan Central Division (panel presided over by A. Postiglione) dismissed Insulet Corporation's application for provisional measures against EOFLOW Co., Ltd.
Read the analysisBy order of 1 October 2024 (UPC_CFI_380/2024, ORD_52068/2024), the Milan Central Division (A. Postiglione, presiding and judge-rapporteur, A.-L.
Read the analysisBy an order of 24 September 2024 (UPC_CFI_380/2024), the panel of the Milan Central Division (A. Postiglione, presiding judge and judge-rapporteur, A.-L.
Read the analysis